#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Obesity and vitamin-D deficiency are two major global public health concerns that affect over one-third of the population .
3-1	17-24	Obesity	abstract	new	coref	8-16[50_0]
3-2	25-28	and	_	_	_	_
3-3	29-38	vitamin-D	abstract[4]	new[4]	coref	3-6[5_4]
3-4	39-49	deficiency	abstract[4]	new[4]	_	_
3-5	50-53	are	_	_	_	_
3-6	54-57	two	abstract[5]	giv[5]	coref	5-10[17_5]
3-7	58-63	major	abstract[5]	giv[5]	_	_
3-8	64-70	global	abstract[5]	giv[5]	_	_
3-9	71-77	public	abstract[5]	giv[5]	_	_
3-10	78-84	health	abstract[5]	giv[5]	_	_
3-11	85-93	concerns	abstract[5]	giv[5]	_	_
3-12	94-98	that	_	_	_	_
3-13	99-105	affect	_	_	_	_
3-14	106-110	over	_	_	_	_
3-15	111-120	one-third	quantity[6]	new[6]	_	_
3-16	121-123	of	quantity[6]	new[6]	_	_
3-17	124-127	the	quantity[6]|person[7]	new[6]|new[7]	coref	23-25[191_7]
3-18	128-138	population	quantity[6]|person[7]	new[6]|new[7]	_	_
3-19	139-140	.	_	_	_	_

#Text=A body mass index of more than 30 kg/m2 is associated with lower serum vitamin-D levels compared with non-obese individuals .
4-1	141-142	A	abstract[10]	new[10]	coref	16-16[120_10]
4-2	143-147	body	object|abstract[10]	new|new[10]	coref	19-6[145_0]
4-3	148-152	mass	quantity|abstract[10]	new|new[10]	_	_
4-4	153-158	index	abstract[10]	new[10]	_	_
4-5	159-161	of	abstract[10]	new[10]	_	_
4-6	162-166	more	abstract[10]|quantity[11]	new[10]|new[11]	_	_
4-7	167-171	than	abstract[10]|quantity[11]	new[10]|new[11]	_	_
4-8	172-174	30	abstract[10]|quantity[11]	new[10]|new[11]	_	_
4-9	175-180	kg/m2	abstract[10]|quantity[11]	new[10]|new[11]	_	_
4-10	181-183	is	_	_	_	_
4-11	184-194	associated	_	_	_	_
4-12	195-199	with	_	_	_	_
4-13	200-205	lower	abstract[13]	new[13]	coref	6-24[27_13]
4-14	206-211	serum	abstract|abstract[13]	new|new[13]	coref	14-11
4-15	212-221	vitamin-D	abstract[13]	new[13]	_	_
4-16	222-228	levels	abstract[13]	new[13]	_	_
4-17	229-237	compared	_	_	_	_
4-18	238-242	with	_	_	_	_
4-19	243-252	non-obese	person[14]	new[14]	coref	6-18[26_14]
4-20	253-264	individuals	person[14]	new[14]	_	_
4-21	265-266	.	_	_	_	_

#Text=Several mechanisms that contribute to the high incidence of vitamin-D deficiency in obese people were suggested .
5-1	267-274	Several	abstract[15]	new[15]	coref	8-35[57_15]
5-2	275-285	mechanisms	abstract[15]	new[15]	_	_
5-3	286-290	that	_	_	_	_
5-4	291-301	contribute	_	_	_	_
5-5	302-304	to	_	_	_	_
5-6	305-308	the	abstract[16]	new[16]	_	_
5-7	309-313	high	abstract[16]	new[16]	_	_
5-8	314-323	incidence	abstract[16]	new[16]	_	_
5-9	324-326	of	abstract[16]	new[16]	_	_
5-10	327-336	vitamin-D	abstract[16]|abstract[17]	new[16]|giv[17]	coref	8-3[44_17]
5-11	337-347	deficiency	abstract[16]|abstract[17]	new[16]|giv[17]	_	_
5-12	348-350	in	abstract[16]|abstract[17]	new[16]|giv[17]	_	_
5-13	351-356	obese	abstract[16]|abstract[17]|person[18]	new[16]|giv[17]|new[18]	_	_
5-14	357-363	people	abstract[16]|abstract[17]|person[18]	new[16]|giv[17]|new[18]	_	_
5-15	364-368	were	_	_	_	_
5-16	369-378	suggested	_	_	_	_
5-17	379-380	.	_	_	_	_

#Text=Ultraviolet radiation from sunlight exposure is required for cutaneous production of vitamin D. It was proposed that obese individuals , overall , have suboptimal levels of vitamin D because they tend to participate in fewer outdoor activities and , accordingly , have less exposure to sunlight .
6-1	381-392	Ultraviolet	abstract[19]	new[19]	_	_
6-2	393-402	radiation	abstract[19]	new[19]	_	_
6-3	403-407	from	abstract[19]	new[19]	_	_
6-4	408-416	sunlight	abstract[19]|substance|abstract[21]	new[19]|new|new[21]	coref|coref	6-43[32_21]|6-43[32_21]
6-5	417-425	exposure	abstract[19]|abstract[21]	new[19]|new[21]	_	_
6-6	426-428	is	_	_	_	_
6-7	429-437	required	_	_	_	_
6-8	438-441	for	_	_	_	_
6-9	442-451	cutaneous	abstract[22]	new[22]	ana	6-14[0_22]
6-10	452-462	production	abstract[22]	new[22]	_	_
6-11	463-465	of	abstract[22]	new[22]	_	_
6-12	466-473	vitamin	abstract[22]|substance	new[22]|new	coref	6-27
6-13	474-476	D.	abstract[22]|person	new[22]|new	coref	8-17
6-14	477-479	It	abstract	giv	coref	22-26[183_0]
6-15	480-483	was	_	_	_	_
6-16	484-492	proposed	_	_	_	_
6-17	493-497	that	_	_	_	_
6-18	498-503	obese	person[26]	giv[26]	ana	6-30[0_26]
6-19	504-515	individuals	person[26]	giv[26]	_	_
6-20	516-517	,	person[26]	giv[26]	_	_
6-21	518-525	overall	person[26]	giv[26]	_	_
6-22	526-527	,	_	_	_	_
6-23	528-532	have	_	_	_	_
6-24	533-543	suboptimal	abstract[27]	giv[27]	coref	14-10[95_27]
6-25	544-550	levels	abstract[27]	giv[27]	_	_
6-26	551-553	of	abstract[27]	giv[27]	_	_
6-27	554-561	vitamin	abstract[27]|substance|person[29]	giv[27]|giv|new[29]	coref|coref|coref|coref	7-1[33_0]|7-17[38_29]|7-1[33_0]|7-17[38_29]
6-28	562-563	D	abstract[27]|person[29]	giv[27]|new[29]	_	_
6-29	564-571	because	_	_	_	_
6-30	572-576	they	person	giv	coref	7-20[39_0]
6-31	577-581	tend	_	_	_	_
6-32	582-584	to	_	_	_	_
6-33	585-596	participate	_	_	_	_
6-34	597-599	in	_	_	_	_
6-35	600-605	fewer	abstract[31]	new[31]	_	_
6-36	606-613	outdoor	abstract[31]	new[31]	_	_
6-37	614-624	activities	abstract[31]	new[31]	_	_
6-38	625-628	and	_	_	_	_
6-39	629-630	,	_	_	_	_
6-40	631-642	accordingly	_	_	_	_
6-41	643-644	,	_	_	_	_
6-42	645-649	have	_	_	_	_
6-43	650-654	less	abstract[32]	giv[32]	ana	7-9[0_32]
6-44	655-663	exposure	abstract[32]	giv[32]	_	_
6-45	664-666	to	abstract[32]	giv[32]	_	_
6-46	667-675	sunlight	abstract[32]	giv[32]	_	_
6-47	676-677	.	_	_	_	_

#Text=Vitamin D is a lipid-soluble vitamin , and it is thought that the lower bioavailability of vitamin D in obese individuals , compared to lean individuals , is due to vitamin-D sequestration within the adipose tissues .
7-1	678-685	Vitamin	substance[33]	giv[33]	coref	7-4[34_33]
7-2	686-687	D	substance[33]	giv[33]	_	_
7-3	688-690	is	_	_	_	_
7-4	691-692	a	substance[34]	giv[34]	coref	7-17[0_34]
7-5	693-706	lipid-soluble	substance[34]	giv[34]	_	_
7-6	707-714	vitamin	substance[34]	giv[34]	_	_
7-7	715-716	,	_	_	_	_
7-8	717-720	and	_	_	_	_
7-9	721-723	it	abstract	giv	_	_
7-10	724-726	is	_	_	_	_
7-11	727-734	thought	_	_	_	_
7-12	735-739	that	_	_	_	_
7-13	740-743	the	substance[36]	new[36]	_	_
7-14	744-749	lower	substance[36]	new[36]	_	_
7-15	750-765	bioavailability	substance[36]	new[36]	_	_
7-16	766-768	of	substance[36]	new[36]	_	_
7-17	769-776	vitamin	substance[36]|substance|person[38]	new[36]|giv|giv[38]	coref|coref|coref|coref	8-16|10-7[0_38]|8-16|10-7[0_38]
7-18	777-778	D	substance[36]|person[38]	new[36]|giv[38]	_	_
7-19	779-781	in	substance[36]	new[36]	_	_
7-20	782-787	obese	substance[36]|person[39]	new[36]|giv[39]	coref	7-26[0_39]
7-21	788-799	individuals	substance[36]|person[39]	new[36]|giv[39]	_	_
7-22	800-801	,	_	_	_	_
7-23	802-810	compared	_	_	_	_
7-24	811-813	to	_	_	_	_
7-25	814-818	lean	_	_	_	_
7-26	819-830	individuals	person	giv	coref	26-17[224_0]
7-27	831-832	,	_	_	_	_
7-28	833-835	is	_	_	_	_
7-29	836-839	due	_	_	_	_
7-30	840-842	to	_	_	_	_
7-31	843-852	vitamin-D	_	_	_	_
7-32	853-866	sequestration	substance	new	_	_
7-33	867-873	within	_	_	_	_
7-34	874-877	the	object[43]	new[43]	coref	19-14[0_43]
7-35	878-885	adipose	abstract|object[43]	new|new[43]	coref	24-27
7-36	886-893	tissues	object[43]	new[43]	_	_
7-37	894-895	.	_	_	_	_

#Text=Lastly , vitamin-D deficiency may also be due to inadequate dietary intake or malabsorption of vitamin D. Obesity is a well-established risk factor for the development of cardiovascular disease ( CVD ) , and several mechanisms may contribute to this link .
8-1	896-902	Lastly	_	_	_	_
8-2	903-904	,	_	_	_	_
8-3	905-914	vitamin-D	abstract[44]	giv[44]	coref	9-6[60_44]
8-4	915-925	deficiency	abstract[44]	giv[44]	_	_
8-5	926-929	may	_	_	_	_
8-6	930-934	also	_	_	_	_
8-7	935-937	be	_	_	_	_
8-8	938-941	due	_	_	_	_
8-9	942-944	to	_	_	_	_
8-10	945-955	inadequate	event[46]	new[46]	coref	15-9[101_46]
8-11	956-963	dietary	abstract|event[46]	new|new[46]	_	_
8-12	964-970	intake	event[46]	new[46]	_	_
8-13	971-973	or	_	_	_	_
8-14	974-987	malabsorption	abstract[47]	new[47]	_	_
8-15	988-990	of	abstract[47]	new[47]	_	_
8-16	991-998	vitamin	abstract[47]|substance|abstract[50]	new[47]|giv|giv[50]	coref|coref|coref|coref	10-6|27-15[0_50]|10-6|27-15[0_50]
8-17	999-1001	D.	abstract[47]|person|abstract[50]	new[47]|giv|giv[50]	_	_
8-18	1002-1009	Obesity	abstract[47]|abstract[50]	new[47]|giv[50]	_	_
8-19	1010-1012	is	_	_	_	_
8-20	1013-1014	a	abstract[52]	new[52]	_	_
8-21	1015-1031	well-established	abstract[52]	new[52]	_	_
8-22	1032-1036	risk	abstract|abstract[52]	new|new[52]	coref	9-14
8-23	1037-1043	factor	abstract[52]	new[52]	_	_
8-24	1044-1047	for	abstract[52]	new[52]	_	_
8-25	1048-1051	the	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-26	1052-1063	development	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-27	1064-1066	of	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-28	1067-1081	cardiovascular	abstract[52]|abstract[53]|abstract|abstract[55]	new[52]|new[53]|new|new[55]	appos|coref|appos|coref	8-31[0_55]|9-9[61_0]|8-31[0_55]|9-9[61_0]
8-29	1082-1089	disease	abstract[52]|abstract[53]|abstract[55]	new[52]|new[53]|new[55]	_	_
8-30	1090-1091	(	_	_	_	_
8-31	1092-1095	CVD	abstract	giv	coref	12-17
8-32	1096-1097	)	_	_	_	_
8-33	1098-1099	,	_	_	_	_
8-34	1100-1103	and	_	_	_	_
8-35	1104-1111	several	abstract[57]	giv[57]	_	_
8-36	1112-1122	mechanisms	abstract[57]	giv[57]	_	_
8-37	1123-1126	may	_	_	_	_
8-38	1127-1137	contribute	_	_	_	_
8-39	1138-1140	to	_	_	_	_
8-40	1141-1145	this	abstract[58]	new[58]	_	_
8-41	1146-1150	link	abstract[58]	new[58]	_	_
8-42	1151-1152	.	_	_	_	_

#Text=However , a role of vitamin-D deficiency in obesity-associated cardiovascular ( CV ) risk is yet to be established .
9-1	1153-1160	However	_	_	_	_
9-2	1161-1162	,	_	_	_	_
9-3	1163-1164	a	abstract[59]	new[59]	_	_
9-4	1165-1169	role	abstract[59]	new[59]	_	_
9-5	1170-1172	of	abstract[59]	new[59]	_	_
9-6	1173-1182	vitamin-D	abstract[59]|abstract[60]	new[59]|giv[60]	coref	10-6[68_60]
9-7	1183-1193	deficiency	abstract[59]|abstract[60]	new[59]|giv[60]	_	_
9-8	1194-1196	in	abstract[59]|abstract[60]	new[59]|giv[60]	_	_
9-9	1197-1215	obesity-associated	abstract[59]|abstract[60]|abstract[61]	new[59]|giv[60]|giv[61]	_	_
9-10	1216-1230	cardiovascular	abstract[59]|abstract[60]|abstract[61]	new[59]|giv[60]|giv[61]	_	_
9-11	1231-1232	(	_	_	_	_
9-12	1233-1235	CV	person	new	_	_
9-13	1236-1237	)	_	_	_	_
9-14	1238-1242	risk	abstract	giv	coref	13-6[88_0]
9-15	1243-1245	is	_	_	_	_
9-16	1246-1249	yet	_	_	_	_
9-17	1250-1252	to	_	_	_	_
9-18	1253-1255	be	_	_	_	_
9-19	1256-1267	established	_	_	_	_
9-20	1268-1269	.	_	_	_	_

#Text=Epidemiological data reported associations between vitamin D deficiency and left ventricular hypertrophy , hypertension , increased arterial stiffness , and endothelial dysfunction .
10-1	1270-1285	Epidemiological	abstract[64]	new[64]	_	_
10-2	1286-1290	data	abstract[64]	new[64]	_	_
10-3	1291-1299	reported	_	_	_	_
10-4	1300-1312	associations	abstract[65]	new[65]	coref	11-5[75_65]
10-5	1313-1320	between	abstract[65]	new[65]	_	_
10-6	1321-1328	vitamin	abstract[65]|substance|abstract[68]	new[65]|giv|giv[68]	coref|coref|coref|coref	12-11|12-25[84_68]|12-11|12-25[84_68]
10-7	1329-1330	D	abstract[65]|person|abstract[68]	new[65]|giv|giv[68]	coref	12-12
10-8	1331-1341	deficiency	abstract[65]|abstract[68]	new[65]|giv[68]	_	_
10-9	1342-1345	and	_	_	_	_
10-10	1346-1350	left	_	_	_	_
10-11	1351-1362	ventricular	abstract[69]	new[69]	_	_
10-12	1363-1374	hypertrophy	abstract[69]	new[69]	_	_
10-13	1375-1376	,	_	_	_	_
10-14	1377-1389	hypertension	abstract	new	coref	12-28
10-15	1390-1391	,	_	_	_	_
10-16	1392-1401	increased	abstract[71]	new[71]	coref	16-22[122_71]
10-17	1402-1410	arterial	abstract[71]	new[71]	_	_
10-18	1411-1420	stiffness	abstract[71]	new[71]	_	_
10-19	1421-1422	,	_	_	_	_
10-20	1423-1426	and	_	_	_	_
10-21	1427-1438	endothelial	abstract|abstract[73]	new|new[73]	coref|coref|coref|coref	19-25|22-21[181_73]|19-25|22-21[181_73]
10-22	1439-1450	dysfunction	abstract[73]	new[73]	_	_
10-23	1451-1452	.	_	_	_	_

#Text=The pathophysiological underpinnings of these associations remain mostly unexplained .
11-1	1453-1456	The	abstract[74]	new[74]	_	_
11-2	1457-1475	pathophysiological	abstract[74]	new[74]	_	_
11-3	1476-1489	underpinnings	abstract[74]	new[74]	_	_
11-4	1490-1492	of	abstract[74]	new[74]	_	_
11-5	1493-1498	these	abstract[74]|abstract[75]	new[74]|giv[75]	_	_
11-6	1499-1511	associations	abstract[74]|abstract[75]	new[74]|giv[75]	_	_
11-7	1512-1518	remain	_	_	_	_
11-8	1519-1525	mostly	_	_	_	_
11-9	1526-1537	unexplained	_	_	_	_
11-10	1538-1539	.	_	_	_	_

#Text=The most reliable and convincing evidence for the involvement of vitamin D in the pathogenesis of CVD comes from studies demonstrating an association between vitamin-D deficiency and hypertension .
12-1	1540-1543	The	abstract[76]	new[76]	coref	23-2[184_76]
12-2	1544-1548	most	abstract[76]	new[76]	_	_
12-3	1549-1557	reliable	abstract[76]	new[76]	_	_
12-4	1558-1561	and	abstract[76]	new[76]	_	_
12-5	1562-1572	convincing	abstract[76]	new[76]	_	_
12-6	1573-1581	evidence	abstract[76]	new[76]	_	_
12-7	1582-1585	for	abstract[76]	new[76]	_	_
12-8	1586-1589	the	abstract[76]|abstract[77]	new[76]|new[77]	_	_
12-9	1590-1601	involvement	abstract[76]|abstract[77]	new[76]|new[77]	_	_
12-10	1602-1604	of	abstract[76]|abstract[77]	new[76]|new[77]	_	_
12-11	1605-1612	vitamin	abstract[76]|abstract[77]|substance	new[76]|new[77]|giv	coref	17-16[130_0]
12-12	1613-1614	D	abstract[76]|abstract[77]|person	new[76]|new[77]|giv	coref	18-13[136_0]
12-13	1615-1617	in	abstract[76]|abstract[77]	new[76]|new[77]	_	_
12-14	1618-1621	the	abstract[76]|abstract[77]|abstract[80]	new[76]|new[77]|new[80]	_	_
12-15	1622-1634	pathogenesis	abstract[76]|abstract[77]|abstract[80]	new[76]|new[77]|new[80]	_	_
12-16	1635-1637	of	abstract[76]|abstract[77]|abstract[80]	new[76]|new[77]|new[80]	_	_
12-17	1638-1641	CVD	abstract[76]|abstract[77]|abstract[80]|event	new[76]|new[77]|new[80]|giv	coref	22-17
12-18	1642-1647	comes	_	_	_	_
12-19	1648-1652	from	_	_	_	_
12-20	1653-1660	studies	event	new	coref	20-1[154_0]
12-21	1661-1674	demonstrating	_	_	_	_
12-22	1675-1677	an	abstract[83]	new[83]	coref	14-3[93_83]
12-23	1678-1689	association	abstract[83]	new[83]	_	_
12-24	1690-1697	between	abstract[83]	new[83]	_	_
12-25	1698-1707	vitamin-D	abstract[83]|abstract[84]|abstract[85]	new[83]|giv[84]|new[85]	coref|coref|coref|coref	13-1[87_84]|22-14[178_85]|13-1[87_84]|22-14[178_85]
12-26	1708-1718	deficiency	abstract[83]|abstract[84]|abstract[85]	new[83]|giv[84]|new[85]	_	_
12-27	1719-1722	and	abstract[83]|abstract[85]	new[83]|new[85]	_	_
12-28	1723-1735	hypertension	abstract[83]|abstract[85]|abstract	new[83]|new[85]|giv	coref	13-18
12-29	1736-1737	.	_	_	_	_

#Text=Vitamin-D deficiency is associated with a higher risk for preeclampsia , a condition that is characterized by hypertension .
13-1	1738-1747	Vitamin-D	abstract[87]	giv[87]	coref	22-14[177_87]
13-2	1748-1758	deficiency	abstract[87]	giv[87]	_	_
13-3	1759-1761	is	_	_	_	_
13-4	1762-1772	associated	_	_	_	_
13-5	1773-1777	with	_	_	_	_
13-6	1778-1779	a	abstract[88]	giv[88]	_	_
13-7	1780-1786	higher	abstract[88]	giv[88]	_	_
13-8	1787-1791	risk	abstract[88]	giv[88]	_	_
13-9	1792-1795	for	abstract[88]	giv[88]	_	_
13-10	1796-1808	preeclampsia	abstract[88]|abstract	giv[88]|new	appos	13-12[90_0]
13-11	1809-1810	,	_	_	_	_
13-12	1811-1812	a	abstract[90]	giv[90]	_	_
13-13	1813-1822	condition	abstract[90]	giv[90]	_	_
13-14	1823-1827	that	_	_	_	_
13-15	1828-1830	is	_	_	_	_
13-16	1831-1844	characterized	_	_	_	_
13-17	1845-1847	by	_	_	_	_
13-18	1848-1860	hypertension	abstract	giv	coref	16-30
13-19	1861-1862	.	_	_	_	_

#Text=Also , a significant inverse association was reported between vitamin-D serum levels and arterial blood pressure in the elderly .
14-1	1863-1867	Also	_	_	_	_
14-2	1868-1869	,	_	_	_	_
14-3	1870-1871	a	abstract[93]	giv[93]	coref	22-11[176_93]
14-4	1872-1883	significant	abstract[93]	giv[93]	_	_
14-5	1884-1891	inverse	place|abstract[93]	new|giv[93]	_	_
14-6	1892-1903	association	abstract[93]	giv[93]	_	_
14-7	1904-1907	was	_	_	_	_
14-8	1908-1916	reported	_	_	_	_
14-9	1917-1924	between	_	_	_	_
14-10	1925-1934	vitamin-D	abstract[95]	giv[95]	_	_
14-11	1935-1940	serum	substance|abstract[95]	giv|giv[95]	_	_
14-12	1941-1947	levels	abstract[95]	giv[95]	_	_
14-13	1948-1951	and	abstract[95]	giv[95]	_	_
14-14	1952-1960	arterial	abstract[95]|abstract[97]	giv[95]|new[97]	coref	15-35[112_97]
14-15	1961-1966	blood	abstract[95]|substance|abstract[97]	giv[95]|new|new[97]	coref	15-31
14-16	1967-1975	pressure	abstract[95]|abstract[97]	giv[95]|new[97]	_	_
14-17	1976-1978	in	abstract[95]|abstract[97]	giv[95]|new[97]	_	_
14-18	1979-1982	the	abstract[95]|abstract[97]	giv[95]|new[97]	_	_
14-19	1983-1990	elderly	abstract[95]|abstract[97]	giv[95]|new[97]	_	_
14-20	1991-1992	.	_	_	_	_

#Text=An interventional study demonstrated that one month of vitamin-D intake ( 1,5000 IU/day ) reduced tissue sensitivity to the stimulation of the renin – angiotensin system manifested by improved renal blood flow and reduced mean arterial pressure during an infusion of angiotensin II .
15-1	1993-1995	An	abstract[98]	new[98]	coref	21-1[166_98]
15-2	1996-2010	interventional	abstract[98]	new[98]	_	_
15-3	2011-2016	study	abstract[98]	new[98]	_	_
15-4	2017-2029	demonstrated	_	_	_	_
15-5	2030-2034	that	time[99]	new[99]	_	_
15-6	2035-2038	one	time[99]	new[99]	_	_
15-7	2039-2044	month	time[99]	new[99]	_	_
15-8	2045-2047	of	time[99]	new[99]	_	_
15-9	2048-2057	vitamin-D	time[99]|substance|event[101]	new[99]|new|giv[101]	coref|coref	16-1[115_101]|16-1[115_101]
15-10	2058-2064	intake	time[99]|event[101]	new[99]|giv[101]	_	_
15-11	2065-2066	(	_	_	_	_
15-12	2067-2073	1,5000	quantity[102]	new[102]	_	_
15-13	2074-2080	IU/day	quantity[102]	new[102]	_	_
15-14	2081-2082	)	_	_	_	_
15-15	2083-2090	reduced	_	_	_	_
15-16	2091-2097	tissue	object|abstract[104]	new|new[104]	coref|coref	24-26[203_0]|24-26[203_0]
15-17	2098-2109	sensitivity	abstract[104]	new[104]	_	_
15-18	2110-2112	to	abstract[104]	new[104]	_	_
15-19	2113-2116	the	abstract[104]|abstract[105]	new[104]|new[105]	_	_
15-20	2117-2128	stimulation	abstract[104]|abstract[105]	new[104]|new[105]	_	_
15-21	2129-2131	of	abstract[104]|abstract[105]	new[104]|new[105]	_	_
15-22	2132-2135	the	abstract[104]|abstract[105]|substance[106]	new[104]|new[105]|new[106]	coref	20-22[162_106]
15-23	2136-2141	renin	abstract[104]|abstract[105]|substance[106]	new[104]|new[105]|new[106]	_	_
15-24	2142-2143	–	_	_	_	_
15-25	2144-2155	angiotensin	person|abstract[108]	new|new[108]	coref|coref|coref|coref	15-42[114_0]|20-27[165_108]|15-42[114_0]|20-27[165_108]
15-26	2156-2162	system	abstract[108]	new[108]	_	_
15-27	2163-2173	manifested	_	_	_	_
15-28	2174-2176	by	_	_	_	_
15-29	2177-2185	improved	abstract[111]	new[111]	_	_
15-30	2186-2191	renal	abstract|abstract[111]	new|new[111]	_	_
15-31	2192-2197	blood	substance|abstract[111]	giv|new[111]	coref	20-17
15-32	2198-2202	flow	abstract[111]	new[111]	_	_
15-33	2203-2206	and	_	_	_	_
15-34	2207-2214	reduced	_	_	_	_
15-35	2215-2219	mean	abstract[112]	giv[112]	coref	20-16[161_112]
15-36	2220-2228	arterial	abstract[112]	giv[112]	_	_
15-37	2229-2237	pressure	abstract[112]	giv[112]	_	_
15-38	2238-2244	during	_	_	_	_
15-39	2245-2247	an	event[113]	new[113]	_	_
15-40	2248-2256	infusion	event[113]	new[113]	_	_
15-41	2257-2259	of	event[113]	new[113]	_	_
15-42	2260-2271	angiotensin	event[113]|person[114]	new[113]|giv[114]	coref	20-25[0_114]
15-43	2272-2274	II	event[113]|person[114]	new[113]|giv[114]	_	_
15-44	2275-2276	.	_	_	_	_

#Text=Moreover , vitamin-D intake ( 2000 IU/day ) for 14 days in healthy adults reduced augmentation index , a measure of arterial stiffness that contributes to the development of hypertension .
16-1	2277-2285	Moreover	event[115]	giv[115]	_	_
16-2	2286-2287	,	event[115]	giv[115]	_	_
16-3	2288-2297	vitamin-D	event[115]	giv[115]	_	_
16-4	2298-2304	intake	event[115]	giv[115]	_	_
16-5	2305-2306	(	_	_	_	_
16-6	2307-2311	2000	quantity[116]	new[116]	_	_
16-7	2312-2318	IU/day	quantity[116]	new[116]	_	_
16-8	2319-2320	)	_	_	_	_
16-9	2321-2324	for	_	_	_	_
16-10	2325-2327	14	time[117]	new[117]	_	_
16-11	2328-2332	days	time[117]	new[117]	_	_
16-12	2333-2335	in	time[117]	new[117]	_	_
16-13	2336-2343	healthy	time[117]|person[118]	new[117]|new[118]	coref	24-33[205_118]
16-14	2344-2350	adults	time[117]|person[118]	new[117]|new[118]	_	_
16-15	2351-2358	reduced	_	_	_	_
16-16	2359-2371	augmentation	abstract|abstract[120]	new|giv[120]	_	_
16-17	2372-2377	index	abstract[120]	giv[120]	_	_
16-18	2378-2379	,	_	_	_	_
16-19	2380-2381	a	abstract[121]	new[121]	_	_
16-20	2382-2389	measure	abstract[121]	new[121]	_	_
16-21	2390-2392	of	abstract[121]	new[121]	_	_
16-22	2393-2401	arterial	abstract[121]|abstract[122]	new[121]|giv[122]	coref	20-9[157_122]
16-23	2402-2411	stiffness	abstract[121]|abstract[122]	new[121]|giv[122]	_	_
16-24	2412-2416	that	_	_	_	_
16-25	2417-2428	contributes	_	_	_	_
16-26	2429-2431	to	_	_	_	_
16-27	2432-2435	the	event[123]	new[123]	_	_
16-28	2436-2447	development	event[123]	new[123]	_	_
16-29	2448-2450	of	event[123]	new[123]	_	_
16-30	2451-2463	hypertension	event[123]|abstract	new[123]|giv	_	_
16-31	2464-2465	.	_	_	_	_

#Text=The discovery of vitamin-D receptor ( VDR ) widened the scope of biological effects that vitamin D plays in human health .
17-1	2466-2469	The	event[125]	new[125]	_	_
17-2	2470-2479	discovery	event[125]	new[125]	_	_
17-3	2480-2482	of	event[125]	new[125]	_	_
17-4	2483-2492	vitamin-D	event[125]|substance[126]	new[125]|new[126]	_	_
17-5	2493-2501	receptor	event[125]|substance[126]	new[125]|new[126]	_	_
17-6	2502-2503	(	_	_	_	_
17-7	2504-2507	VDR	abstract	new	coref	18-1
17-8	2508-2509	)	_	_	_	_
17-9	2510-2517	widened	_	_	_	_
17-10	2518-2521	the	abstract[128]	new[128]	_	_
17-11	2522-2527	scope	abstract[128]	new[128]	_	_
17-12	2528-2530	of	abstract[128]	new[128]	_	_
17-13	2531-2541	biological	abstract[128]|abstract[129]	new[128]|new[129]	coref	24-10[196_129]
17-14	2542-2549	effects	abstract[128]|abstract[129]	new[128]|new[129]	_	_
17-15	2550-2554	that	_	_	_	_
17-16	2555-2562	vitamin	substance[130]	giv[130]	coref	18-13[0_130]
17-17	2563-2564	D	substance[130]	giv[130]	_	_
17-18	2565-2570	plays	_	_	_	_
17-19	2571-2573	in	_	_	_	_
17-20	2574-2579	human	abstract[131]	new[131]	_	_
17-21	2580-2586	health	abstract[131]	new[131]	_	_
17-22	2587-2588	.	_	_	_	_

#Text=VDR is a transcription factor that enters the nucleus upon binding to vitamin D , where it attaches to specific DNA regions and activates the transcription of a myriad of genes that coordinate several biological responses .
18-1	2589-2592	VDR	abstract	giv	coref	18-3[133_0]
18-2	2593-2595	is	_	_	_	_
18-3	2596-2597	a	abstract[133]	giv[133]	coref	19-1[0_133]
18-4	2598-2611	transcription	abstract[133]	giv[133]	_	_
18-5	2612-2618	factor	abstract[133]	giv[133]	_	_
18-6	2619-2623	that	_	_	_	_
18-7	2624-2630	enters	_	_	_	_
18-8	2631-2634	the	place[134]	new[134]	_	_
18-9	2635-2642	nucleus	place[134]	new[134]	_	_
18-10	2643-2647	upon	_	_	_	_
18-11	2648-2655	binding	_	_	_	_
18-12	2656-2658	to	_	_	_	_
18-13	2659-2666	vitamin	substance|substance[136]	giv|giv[136]	ana|coref|ana|coref	18-17[0_136]|23-9[186_0]|18-17[0_136]|23-9[186_0]
18-14	2667-2668	D	substance[136]	giv[136]	_	_
18-15	2669-2670	,	_	_	_	_
18-16	2671-2676	where	_	_	_	_
18-17	2677-2679	it	substance	giv	coref	24-13[198_0]
18-18	2680-2688	attaches	_	_	_	_
18-19	2689-2691	to	_	_	_	_
18-20	2692-2700	specific	place[139]	new[139]	_	_
18-21	2701-2704	DNA	substance|place[139]	new|new[139]	_	_
18-22	2705-2712	regions	place[139]	new[139]	_	_
18-23	2713-2716	and	_	_	_	_
18-24	2717-2726	activates	_	_	_	_
18-25	2727-2730	the	event[140]	new[140]	_	_
18-26	2731-2744	transcription	event[140]	new[140]	_	_
18-27	2745-2747	of	event[140]	new[140]	_	_
18-28	2748-2749	a	event[140]|abstract[141]	new[140]|new[141]	_	_
18-29	2750-2756	myriad	event[140]|abstract[141]	new[140]|new[141]	_	_
18-30	2757-2759	of	event[140]|abstract[141]	new[140]|new[141]	_	_
18-31	2760-2765	genes	event[140]|abstract[141]|abstract	new[140]|new[141]|new	_	_
18-32	2766-2770	that	_	_	_	_
18-33	2771-2781	coordinate	_	_	_	_
18-34	2782-2789	several	event[143]	new[143]	_	_
18-35	2790-2800	biological	event[143]	new[143]	_	_
18-36	2801-2810	responses	event[143]	new[143]	_	_
18-37	2811-2812	.	_	_	_	_

#Text=VDR is widely expressed throughout the human body in almost all cells and tissues , including vascular smooth muscle cells , cardiomyocytes , and endothelial cells .
19-1	2813-2816	VDR	abstract	giv	coref	20-7
19-2	2817-2819	is	_	_	_	_
19-3	2820-2826	widely	_	_	_	_
19-4	2827-2836	expressed	_	_	_	_
19-5	2837-2847	throughout	_	_	_	_
19-6	2848-2851	the	object[145]	giv[145]	_	_
19-7	2852-2857	human	object[145]	giv[145]	_	_
19-8	2858-2862	body	object[145]	giv[145]	_	_
19-9	2863-2865	in	object[145]	giv[145]	_	_
19-10	2866-2872	almost	object[145]|object[146]	giv[145]|new[146]	_	_
19-11	2873-2876	all	object[145]|object[146]	giv[145]|new[146]	_	_
19-12	2877-2882	cells	object[145]|object[146]	giv[145]|new[146]	_	_
19-13	2883-2886	and	object[145]	giv[145]	_	_
19-14	2887-2894	tissues	object[145]|object	giv[145]|giv	_	_
19-15	2895-2896	,	object[145]	giv[145]	_	_
19-16	2897-2906	including	object[145]	giv[145]	_	_
19-17	2907-2915	vascular	object[145]|object[149]	giv[145]|new[149]	_	_
19-18	2916-2922	smooth	object[145]|object[149]	giv[145]|new[149]	_	_
19-19	2923-2929	muscle	object[145]|object|object[149]	giv[145]|new|new[149]	_	_
19-20	2930-2935	cells	object[145]|object[149]	giv[145]|new[149]	_	_
19-21	2936-2937	,	object[145]	giv[145]	_	_
19-22	2938-2952	cardiomyocytes	object[145]|object	giv[145]|new	_	_
19-23	2953-2954	,	object[145]	giv[145]	_	_
19-24	2955-2958	and	object[145]	giv[145]	_	_
19-25	2959-2970	endothelial	object[145]|object|object[152]	giv[145]|giv|new[152]	coref|coref	22-21|22-21
19-26	2971-2976	cells	object[145]|object[152]	giv[145]|new[152]	_	_
19-27	2977-2978	.	_	_	_	_

#Text=Animal studies found that loss of VDR signaling increased arterial stiffness and elevated systolic and diastolic blood pressure , independent of the renin – angiotensin – aldosterone system .
20-1	2979-2985	Animal	person|event[154]	new|giv[154]	coref|coref	22-1[174_154]|22-1[174_154]
20-2	2986-2993	studies	event[154]	giv[154]	_	_
20-3	2994-2999	found	_	_	_	_
20-4	3000-3004	that	abstract[155]	new[155]	coref	23-34[193_155]
20-5	3005-3009	loss	abstract[155]	new[155]	_	_
20-6	3010-3012	of	abstract[155]	new[155]	_	_
20-7	3013-3016	VDR	abstract[155]|abstract	new[155]|giv	coref	21-5
20-8	3017-3026	signaling	_	_	_	_
20-9	3027-3036	increased	abstract[157]	giv[157]	coref	21-10[170_157]
20-10	3037-3045	arterial	abstract[157]	giv[157]	_	_
20-11	3046-3055	stiffness	abstract[157]	giv[157]	_	_
20-12	3056-3059	and	_	_	_	_
20-13	3060-3068	elevated	abstract[158]	new[158]	_	_
20-14	3069-3077	systolic	abstract[158]	new[158]	_	_
20-15	3078-3081	and	_	_	_	_
20-16	3082-3091	diastolic	person|abstract[161]	new|giv[161]	_	_
20-17	3092-3097	blood	substance|abstract[161]	giv|giv[161]	_	_
20-18	3098-3106	pressure	abstract[161]	giv[161]	_	_
20-19	3107-3108	,	abstract[161]	giv[161]	_	_
20-20	3109-3120	independent	abstract[161]	giv[161]	_	_
20-21	3121-3123	of	_	_	_	_
20-22	3124-3127	the	substance[162]	giv[162]	_	_
20-23	3128-3133	renin	substance[162]	giv[162]	_	_
20-24	3134-3135	–	_	_	_	_
20-25	3136-3147	angiotensin	person	giv	_	_
20-26	3148-3149	–	_	_	_	_
20-27	3150-3161	aldosterone	object|abstract[165]	new|giv[165]	coref|coref	28-2[231_165]|28-2[231_165]
20-28	3162-3168	system	abstract[165]	giv[165]	_	_
20-29	3169-3170	.	_	_	_	_

#Text=Another study found that VDR knockout mice have increased arterial stiffness through decreased bioavailability of nitric oxide ( NO ) .
21-1	3171-3178	Another	abstract[166]	giv[166]	coref	24-4[195_166]
21-2	3179-3184	study	abstract[166]	giv[166]	_	_
21-3	3185-3190	found	_	_	_	_
21-4	3191-3195	that	_	_	_	_
21-5	3196-3199	VDR	abstract|abstract[169]	giv|new[169]	_	_
21-6	3200-3208	knockout	event|abstract[169]	new|new[169]	_	_
21-7	3209-3213	mice	abstract[169]	new[169]	_	_
21-8	3214-3218	have	_	_	_	_
21-9	3219-3228	increased	_	_	_	_
21-10	3229-3237	arterial	abstract[170]	giv[170]	_	_
21-11	3238-3247	stiffness	abstract[170]	giv[170]	_	_
21-12	3248-3255	through	_	_	_	_
21-13	3256-3265	decreased	substance[171]	new[171]	_	_
21-14	3266-3281	bioavailability	substance[171]	new[171]	_	_
21-15	3282-3284	of	substance[171]	new[171]	_	_
21-16	3285-3291	nitric	substance[171]|abstract|substance[173]	new[171]|new|new[173]	_	_
21-17	3292-3297	oxide	substance[171]|substance[173]	new[171]|new[173]	_	_
21-18	3298-3299	(	_	_	_	_
21-19	3300-3302	NO	_	_	_	_
21-20	3303-3304	)	_	_	_	_
21-21	3305-3306	.	_	_	_	_

#Text=These and other studies proposed that the leading mechanism for the association between vitamin-D deficiency and CVD is related to endothelial dysfunction and impaired endothelial-dependent NO production .
22-1	3307-3312	These	event[174]	giv[174]	_	_
22-2	3313-3316	and	event[174]	giv[174]	_	_
22-3	3317-3322	other	event[174]	giv[174]	_	_
22-4	3323-3330	studies	event[174]	giv[174]	_	_
22-5	3331-3339	proposed	_	_	_	_
22-6	3340-3344	that	_	_	_	_
22-7	3345-3348	the	abstract[175]	new[175]	_	_
22-8	3349-3356	leading	abstract[175]	new[175]	_	_
22-9	3357-3366	mechanism	abstract[175]	new[175]	_	_
22-10	3367-3370	for	abstract[175]	new[175]	_	_
22-11	3371-3374	the	abstract[175]|abstract[176]	new[175]|giv[176]	_	_
22-12	3375-3386	association	abstract[175]|abstract[176]	new[175]|giv[176]	_	_
22-13	3387-3394	between	abstract[175]|abstract[176]	new[175]|giv[176]	_	_
22-14	3395-3404	vitamin-D	abstract[175]|abstract[176]|abstract[177]|abstract[178]	new[175]|giv[176]|giv[177]|giv[178]	_	_
22-15	3405-3415	deficiency	abstract[175]|abstract[176]|abstract[177]|abstract[178]	new[175]|giv[176]|giv[177]|giv[178]	_	_
22-16	3416-3419	and	abstract[175]|abstract[176]|abstract[178]	new[175]|giv[176]|giv[178]	_	_
22-17	3420-3423	CVD	abstract[175]|abstract[176]|abstract[178]|event	new[175]|giv[176]|giv[178]|giv	_	_
22-18	3424-3426	is	_	_	_	_
22-19	3427-3434	related	_	_	_	_
22-20	3435-3437	to	_	_	_	_
22-21	3438-3449	endothelial	abstract|abstract[181]	giv|giv[181]	_	_
22-22	3450-3461	dysfunction	abstract[181]	giv[181]	_	_
22-23	3462-3465	and	_	_	_	_
22-24	3466-3474	impaired	person[182]	new[182]	_	_
22-25	3475-3496	endothelial-dependent	person[182]	new[182]	_	_
22-26	3497-3499	NO	abstract[183]	giv[183]	coref	25-18[215_183]
22-27	3500-3510	production	abstract[183]	giv[183]	_	_
22-28	3511-3512	.	_	_	_	_

#Text=Despite this accumulating evidence of the role of vitamin D in vascular function , direct mechanistic evidence of this role in the microvasculature of morbidly obese population and how it might be modified following massive weight loss are largely unexplored .
23-1	3513-3520	Despite	_	_	_	_
23-2	3521-3525	this	abstract[184]	giv[184]	coref	23-15[188_184]
23-3	3526-3538	accumulating	abstract[184]	giv[184]	_	_
23-4	3539-3547	evidence	abstract[184]	giv[184]	_	_
23-5	3548-3550	of	abstract[184]	giv[184]	_	_
23-6	3551-3554	the	abstract[184]|abstract[185]	giv[184]|new[185]	coref	23-19[189_185]
23-7	3555-3559	role	abstract[184]|abstract[185]	giv[184]|new[185]	_	_
23-8	3560-3562	of	abstract[184]|abstract[185]	giv[184]|new[185]	_	_
23-9	3563-3570	vitamin	abstract[184]|abstract[185]|substance[186]	giv[184]|new[185]|giv[186]	coref	24-13[0_186]
23-10	3571-3572	D	abstract[184]|abstract[185]|substance[186]	giv[184]|new[185]|giv[186]	_	_
23-11	3573-3575	in	abstract[184]|abstract[185]|substance[186]	giv[184]|new[185]|giv[186]	_	_
23-12	3576-3584	vascular	abstract[184]|abstract[185]|substance[186]|abstract[187]	giv[184]|new[185]|giv[186]|new[187]	coref	25-10[213_187]
23-13	3585-3593	function	abstract[184]|abstract[185]|substance[186]|abstract[187]	giv[184]|new[185]|giv[186]|new[187]	_	_
23-14	3594-3595	,	_	_	_	_
23-15	3596-3602	direct	abstract[188]	giv[188]	_	_
23-16	3603-3614	mechanistic	abstract[188]	giv[188]	_	_
23-17	3615-3623	evidence	abstract[188]	giv[188]	_	_
23-18	3624-3626	of	abstract[188]	giv[188]	_	_
23-19	3627-3631	this	abstract[188]|abstract[189]	giv[188]|giv[189]	_	_
23-20	3632-3636	role	abstract[188]|abstract[189]	giv[188]|giv[189]	_	_
23-21	3637-3639	in	abstract[188]	giv[188]	_	_
23-22	3640-3643	the	abstract[188]|abstract[190]	giv[188]|new[190]	ana	23-30[0_190]
23-23	3644-3660	microvasculature	abstract[188]|abstract[190]	giv[188]|new[190]	_	_
23-24	3661-3663	of	abstract[188]|abstract[190]	giv[188]|new[190]	_	_
23-25	3664-3672	morbidly	abstract[188]|abstract[190]|person[191]	giv[188]|new[190]|giv[191]	_	_
23-26	3673-3678	obese	abstract[188]|abstract[190]|person[191]	giv[188]|new[190]|giv[191]	_	_
23-27	3679-3689	population	abstract[188]|abstract[190]|person[191]	giv[188]|new[190]|giv[191]	_	_
23-28	3690-3693	and	_	_	_	_
23-29	3694-3697	how	_	_	_	_
23-30	3698-3700	it	abstract	giv	coref	24-16[199_0]
23-31	3701-3706	might	_	_	_	_
23-32	3707-3709	be	_	_	_	_
23-33	3710-3718	modified	_	_	_	_
23-34	3719-3728	following	abstract[193]	giv[193]	coref	24-39[208_193]
23-35	3729-3736	massive	abstract[193]	giv[193]	_	_
23-36	3737-3743	weight	abstract[193]	giv[193]	_	_
23-37	3744-3748	loss	abstract[193]	giv[193]	_	_
23-38	3749-3752	are	_	_	_	_
23-39	3753-3760	largely	_	_	_	_
23-40	3761-3771	unexplored	_	_	_	_
23-41	3772-3773	.	_	_	_	_

#Text=The purpose of the current study is to investigate the effects of vitamin D on the microvasculature isolated from both subcutaneous ( SAT ) and visceral adipose tissue ( VAT ) in morbidly obese adults before and after bariatric surgery-induced weight loss .
24-1	3774-3777	The	abstract[194]	new[194]	_	_
24-2	3778-3785	purpose	abstract[194]	new[194]	_	_
24-3	3786-3788	of	abstract[194]	new[194]	_	_
24-4	3789-3792	the	abstract[194]|abstract[195]	new[194]|giv[195]	coref	28-8[232_195]
24-5	3793-3800	current	abstract[194]|abstract[195]	new[194]|giv[195]	_	_
24-6	3801-3806	study	abstract[194]|abstract[195]	new[194]|giv[195]	_	_
24-7	3807-3809	is	_	_	_	_
24-8	3810-3812	to	_	_	_	_
24-9	3813-3824	investigate	_	_	_	_
24-10	3825-3828	the	abstract[196]	giv[196]	coref	28-21[235_196]
24-11	3829-3836	effects	abstract[196]	giv[196]	_	_
24-12	3837-3839	of	abstract[196]	giv[196]	_	_
24-13	3840-3847	vitamin	abstract[196]|substance|person[198]	giv[196]|giv|giv[198]	coref|coref|coref|coref	25-6|25-6[211_198]|25-6|25-6[211_198]
24-14	3848-3849	D	abstract[196]|person[198]	giv[196]|giv[198]	_	_
24-15	3850-3852	on	abstract[196]|person[198]	giv[196]|giv[198]	_	_
24-16	3853-3856	the	abstract[196]|person[198]|abstract[199]	giv[196]|giv[198]|giv[199]	_	_
24-17	3857-3873	microvasculature	abstract[196]|person[198]|abstract[199]	giv[196]|giv[198]|giv[199]	_	_
24-18	3874-3882	isolated	abstract[196]	giv[196]	_	_
24-19	3883-3887	from	abstract[196]	giv[196]	_	_
24-20	3888-3892	both	abstract[196]|person[200]	giv[196]|new[200]	_	_
24-21	3893-3905	subcutaneous	abstract[196]|person[200]	giv[196]|new[200]	_	_
24-22	3906-3907	(	abstract[196]	giv[196]	_	_
24-23	3908-3911	SAT	abstract[196]|object	giv[196]|new	_	_
24-24	3912-3913	)	abstract[196]	giv[196]	_	_
24-25	3914-3917	and	abstract[196]	giv[196]	_	_
24-26	3918-3926	visceral	abstract[196]|object[203]	giv[196]|giv[203]	appos	24-30[0_203]
24-27	3927-3934	adipose	abstract[196]|abstract|object[203]	giv[196]|giv|giv[203]	_	_
24-28	3935-3941	tissue	abstract[196]|object[203]	giv[196]|giv[203]	_	_
24-29	3942-3943	(	_	_	_	_
24-30	3944-3947	VAT	object	giv	_	_
24-31	3948-3949	)	_	_	_	_
24-32	3950-3952	in	_	_	_	_
24-33	3953-3961	morbidly	person[205]	giv[205]	coref	25-13[214_205]
24-34	3962-3967	obese	person[205]	giv[205]	_	_
24-35	3968-3974	adults	person[205]	giv[205]	_	_
24-36	3975-3981	before	person[205]	giv[205]	_	_
24-37	3982-3985	and	person[205]	giv[205]	_	_
24-38	3986-3991	after	person[205]	giv[205]	_	_
24-39	3992-4001	bariatric	person[205]|abstract|abstract[208]	giv[205]|new|giv[208]	coref|coref	25-34[218_208]|25-34[218_208]
24-40	4002-4017	surgery-induced	person[205]|abstract[208]	giv[205]|giv[208]	_	_
24-41	4018-4024	weight	person[205]|place|abstract[208]	giv[205]|new|giv[208]	_	_
24-42	4025-4029	loss	person[205]|abstract[208]	giv[205]|giv[208]	_	_
24-43	4030-4031	.	_	_	_	_

#Text=The central hypothesis is that vitamin D would improve microvascular function in obese adults via improving flow-mediated NO production , and this effect would be of a greater magnitude before compared to after weight loss .
25-1	4032-4035	The	abstract[209]	new[209]	_	_
25-2	4036-4043	central	abstract[209]	new[209]	_	_
25-3	4044-4054	hypothesis	abstract[209]	new[209]	_	_
25-4	4055-4057	is	_	_	_	_
25-5	4058-4062	that	_	_	_	_
25-6	4063-4070	vitamin	substance|substance[211]	giv|giv[211]	_	_
25-7	4071-4072	D	substance[211]	giv[211]	_	_
25-8	4073-4078	would	_	_	_	_
25-9	4079-4086	improve	_	_	_	_
25-10	4087-4100	microvascular	abstract|abstract[213]	new|giv[213]	coref|coref|coref|coref	28-24|28-24[237_213]|28-24|28-24[237_213]
25-11	4101-4109	function	abstract[213]	giv[213]	_	_
25-12	4110-4112	in	abstract[213]	giv[213]	_	_
25-13	4113-4118	obese	abstract[213]|person[214]	giv[213]|giv[214]	_	_
25-14	4119-4125	adults	abstract[213]|person[214]	giv[213]|giv[214]	_	_
25-15	4126-4129	via	_	_	_	_
25-16	4130-4139	improving	_	_	_	_
25-17	4140-4153	flow-mediated	_	_	_	_
25-18	4154-4156	NO	abstract[215]	giv[215]	_	_
25-19	4157-4167	production	abstract[215]	giv[215]	_	_
25-20	4168-4169	,	_	_	_	_
25-21	4170-4173	and	_	_	_	_
25-22	4174-4178	this	abstract[216]	new[216]	_	_
25-23	4179-4185	effect	abstract[216]	new[216]	_	_
25-24	4186-4191	would	_	_	_	_
25-25	4192-4194	be	_	_	_	_
25-26	4195-4197	of	_	_	_	_
25-27	4198-4199	a	abstract[217]	new[217]	_	_
25-28	4200-4207	greater	abstract[217]	new[217]	_	_
25-29	4208-4217	magnitude	abstract[217]	new[217]	_	_
25-30	4218-4224	before	_	_	_	_
25-31	4225-4233	compared	_	_	_	_
25-32	4234-4236	to	_	_	_	_
25-33	4237-4242	after	_	_	_	_
25-34	4243-4249	weight	abstract[218]	giv[218]	_	_
25-35	4250-4254	loss	abstract[218]	giv[218]	_	_
25-36	4255-4256	.	_	_	_	_

#Text=In our previous work , we found that flow-induced dilation ( FID ) is impaired in morbidly obese individuals due to an imbalance of NO and H2O2 .
26-1	4257-4259	In	_	_	_	_
26-2	4260-4263	our	person|abstract[220]	acc|new[220]	ana|ana	26-6|26-6
26-3	4264-4272	previous	abstract[220]	new[220]	_	_
26-4	4273-4277	work	abstract[220]	new[220]	_	_
26-5	4278-4279	,	_	_	_	_
26-6	4280-4282	we	person	giv	ana	28-11
26-7	4283-4288	found	_	_	_	_
26-8	4289-4293	that	abstract[222]	new[222]	appos	26-12[0_222]
26-9	4294-4306	flow-induced	abstract[222]	new[222]	_	_
26-10	4307-4315	dilation	abstract[222]	new[222]	_	_
26-11	4316-4317	(	_	_	_	_
26-12	4318-4321	FID	abstract	giv	_	_
26-13	4322-4323	)	_	_	_	_
26-14	4324-4326	is	_	_	_	_
26-15	4327-4335	impaired	_	_	_	_
26-16	4336-4338	in	_	_	_	_
26-17	4339-4347	morbidly	person[224]	giv[224]	_	_
26-18	4348-4353	obese	person[224]	giv[224]	_	_
26-19	4354-4365	individuals	person[224]	giv[224]	_	_
26-20	4366-4369	due	_	_	_	_
26-21	4370-4372	to	_	_	_	_
26-22	4373-4375	an	abstract[225]	new[225]	_	_
26-23	4376-4385	imbalance	abstract[225]	new[225]	_	_
26-24	4386-4388	of	_	_	_	_
26-25	4389-4391	NO	abstract[226]	new[226]	coref	27-1[0_226]
26-26	4392-4395	and	abstract[226]	new[226]	_	_
26-27	4396-4400	H2O2	abstract[226]	new[226]	_	_
26-28	4401-4402	.	_	_	_	_

#Text=H2O2 may serve as a compensatory mechanism for vasodilation during pathological conditions such as obesity .
27-1	4403-4407	H2O2	abstract	giv	coref	28-27[238_0]
27-2	4408-4411	may	_	_	_	_
27-3	4412-4417	serve	_	_	_	_
27-4	4418-4420	as	_	_	_	_
27-5	4421-4422	a	_	_	_	_
27-6	4423-4435	compensatory	_	_	_	_
27-7	4436-4445	mechanism	_	_	_	_
27-8	4446-4449	for	_	_	_	_
27-9	4450-4462	vasodilation	substance[228]	new[228]	_	_
27-10	4463-4469	during	substance[228]	new[228]	_	_
27-11	4470-4482	pathological	substance[228]|abstract[229]	new[228]|new[229]	_	_
27-12	4483-4493	conditions	substance[228]|abstract[229]	new[228]|new[229]	_	_
27-13	4494-4498	such	substance[228]|abstract[229]	new[228]|new[229]	_	_
27-14	4499-4501	as	substance[228]|abstract[229]	new[228]|new[229]	_	_
27-15	4502-4509	obesity	substance[228]|abstract[229]|abstract	new[228]|new[229]|giv	_	_
27-16	4510-4511	.	_	_	_	_

#Text=Using the proposed ex vivo system in this study , we are able to explore the contributing vasoactive mediators of vitamin-D effects on microvascular function , mainly NO and H2O2 .
28-1	4512-4517	Using	_	_	_	_
28-2	4518-4521	the	abstract[231]	giv[231]	_	_
28-3	4522-4530	proposed	abstract[231]	giv[231]	_	_
28-4	4531-4533	ex	abstract[231]	giv[231]	_	_
28-5	4534-4538	vivo	abstract[231]	giv[231]	_	_
28-6	4539-4545	system	abstract[231]	giv[231]	_	_
28-7	4546-4548	in	_	_	_	_
28-8	4549-4553	this	abstract[232]	giv[232]	_	_
28-9	4554-4559	study	abstract[232]	giv[232]	_	_
28-10	4560-4561	,	_	_	_	_
28-11	4562-4564	we	person	giv	_	_
28-12	4565-4568	are	_	_	_	_
28-13	4569-4573	able	_	_	_	_
28-14	4574-4576	to	_	_	_	_
28-15	4577-4584	explore	_	_	_	_
28-16	4585-4588	the	person[234]	new[234]	_	_
28-17	4589-4601	contributing	person[234]	new[234]	_	_
28-18	4602-4612	vasoactive	person[234]	new[234]	_	_
28-19	4613-4622	mediators	person[234]	new[234]	_	_
28-20	4623-4625	of	person[234]	new[234]	_	_
28-21	4626-4635	vitamin-D	person[234]|abstract[235]	new[234]|giv[235]	_	_
28-22	4636-4643	effects	person[234]|abstract[235]	new[234]|giv[235]	_	_
28-23	4644-4646	on	person[234]|abstract[235]	new[234]|giv[235]	_	_
28-24	4647-4660	microvascular	person[234]|abstract[235]|abstract|abstract[237]	new[234]|giv[235]|giv|giv[237]	_	_
28-25	4661-4669	function	person[234]|abstract[235]|abstract[237]	new[234]|giv[235]|giv[237]	_	_
28-26	4670-4671	,	person[234]|abstract[235]	new[234]|giv[235]	_	_
28-27	4672-4678	mainly	person[234]|abstract[235]|abstract[238]	new[234]|giv[235]|giv[238]	_	_
28-28	4679-4681	NO	person[234]|abstract[235]|abstract[238]	new[234]|giv[235]|giv[238]	_	_
28-29	4682-4685	and	person[234]|abstract[235]|abstract[238]	new[234]|giv[235]|giv[238]	_	_
28-30	4686-4690	H2O2	person[234]|abstract[235]|abstract[238]	new[234]|giv[235]|giv[238]	_	_
28-31	4691-4692	.	_	_	_	_
